Medication info
EPIUM Tablets 40 mg (Esomeprazole Magnesium Trihydrate)

EPIUM Tablets 40 mg (Esomeprazole Magnesium Trihydrate)

Prescription medicationTabletOral · Intravenous injection
Ingredient · strength
Esomeprazole Magnesium Trihydrate›44.5mg / 1 tablet
Manufacturer / importer
Medica Korea Co., Ltd.
Appearance
Pink round film-coated tablet
Packaging
28 tablets/box [14 tablets/PTP (Alu-Alu)*2]
Approval status
Active

MFDS item code 201508477 · Approved 2015.12.29 · Insurance code 646004080

Summary

Main use
Treatment of reflux disease, gastrointestinal disorders (e.g., ulcers and pain), and Zollinger-Ellison syndrome
Who uses it
Adults · Children
Adult dosage
This medicine should be swallowed with a liquid such as water. Do not chew or crush it. 1. Adults 1) Gastroesophageal reflux disease (GERD) - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. Patients whose esophagitis has not healed or whose symptoms persist should take it for an additional 4 weeks. - Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20 mg once daily - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further medical evaluation is needed. · Once symptoms have resolved, subsequent symptoms may be controlled with 20 mg once daily. · In adults, 20 mg may be taken once daily as needed. As-needed use to control recurring symptoms is not recommended for patients at high risk of gastric and duodenal ulcers due to nonsteroidal anti-inflammatory drug use. 2) Combination therapy with antibiotics for Helicobacter pylori eradication Administer this medicine 20 mg with amoxicillin 1 g and clarithromycin 500 mg twice daily for 7 days. 3) Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, burning sensation) associated with the use of nonsteroidal anti-inflammatory drugs (nonselective or selective COX-2 inhibitors) - 20 mg once daily. If symptoms are not controlled after 4 weeks, further medical evaluation is needed. Clinical studies extending beyond 4 weeks have not been conducted. 4) Patients requiring continued treatment with nonsteroidal anti-inflammatory drugs - Treatment of gastric ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. The treatment period is 4∼8 weeks. - Prevention of gastric and duodenal ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. 5) Treatment of Zollinger-Ellison syndrome The recommended initial dose is 40 mg twice daily. The dose should then be adjusted individually, and treatment should continue while clinical symptoms are present. According to clinical data, most patients can be controlled with doses of 80 ∼ 160 mg per day. Doses greater than 80 mg per day should be divided into two doses. 6) Maintenance therapy following intravenous induction to prevent rebleeding due to gastric or duodenal ulcers After intravenous induction to prevent rebleeding due to gastric or duodenal ulcers, administer 40 mg once daily for 4 weeks. 4. Renal impairment No dose adjustment is necessary. Use with caution because there is limited experience with administration to patients with severe renal impairment. 5. Hepatic impairment No dose adjustment is necessary in patients with mild to moderate hepatic impairment. Patients with severe hepatic impairment should not exceed a dose of 20 mg of this medicine. 6. Elderly patients No dose adjustment is necessary.
Children's dosage
Adolescents 12 years of age and older - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. Patients whose esophagitis has not healed or whose symptoms persist should take it for an additional 4 weeks. Adolescents 12 years of age and older - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: 20 mg once daily. If symptoms are not controlled after 4 weeks, further medical evaluation is needed. Once symptoms have resolved, subsequent symptoms may be controlled with 20 mg once daily. In adults, 20 mg may be taken once daily as needed. As-needed use to control recurring symptoms is not recommended for patients at high risk of gastric and duodenal ulcers due to nonsteroidal anti-inflammatory drug use. Children under 12 years of age - There is no experience with administering this medicine to children under 12 years of age.

Ingredients

Manufacturer
Medica Korea Co., Ltd.

Efficacy & effects

Treatment of reflux disease, gastrointestinal disorders (e.g., ulcers and pain), and Zollinger-Ellison syndrome

  • Gastroesophageal reflux disease
  • erosive esophagitis
  • esophagitis
  • duodenal ulcers
  • peptic ulcers
  • upper gastrointestinal tract pain
  • upper gastrointestinal tract discomfort
  • upper gastrointestinal tract burning
  • gastric ulcers
  • duodenal ulcers
  • Zollinger-Ellison syndrome
  • rebleeding of gastric ulcers
View approved original text

This medication is used for the treatment of gastroesophageal reflux disease and erosive esophagitis, as well as for long-term maintenance therapy to prevent recurrence of esophagitis. It also helps treat duodenal ulcers and peptic ulcers confirmed to be positive for Helicobacter pylori and prevents recurrence. It provides short-term relief from symptoms such as pain, discomfort, and burning in the upper gastrointestinal tract associated with the use of non-steroidal anti-inflammatory drugs. It is effective in treating and preventing gastric ulcers in patients on continuous non-steroidal anti-inflammatory drug therapy. Additionally, it is used for the treatment of Zollinger-Ellison syndrome and for maintenance therapy after preventing bleeding from gastric ulcers and duodenal ulcers.

Dosage and Administration

Adult dosage

This medicine should be swallowed with a liquid such as water. Do not chew or crush it. 1. Adults 1) Gastroesophageal reflux disease (GERD) - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. Patients whose esophagitis has not healed or whose symptoms persist should take it for an additional 4 weeks. - Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20 mg once daily - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further medical evaluation is needed. · Once symptoms have resolved, subsequent symptoms may be controlled with 20 mg once daily. · In adults, 20 mg may be taken once daily as needed. As-needed use to control recurring symptoms is not recommended for patients at high risk of gastric and duodenal ulcers due to nonsteroidal anti-inflammatory drug use. 2) Combination therapy with antibiotics for Helicobacter pylori eradication Administer this medicine 20 mg with amoxicillin 1 g and clarithromycin 500 mg twice daily for 7 days. 3) Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, burning sensation) associated with the use of nonsteroidal anti-inflammatory drugs (nonselective or selective COX-2 inhibitors) - 20 mg once daily. If symptoms are not controlled after 4 weeks, further medical evaluation is needed. Clinical studies extending beyond 4 weeks have not been conducted. 4) Patients requiring continued treatment with nonsteroidal anti-inflammatory drugs - Treatment of gastric ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. The treatment period is 4∼8 weeks. - Prevention of gastric and duodenal ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. 5) Treatment of Zollinger-Ellison syndrome The recommended initial dose is 40 mg twice daily. The dose should then be adjusted individually, and treatment should continue while clinical symptoms are present. According to clinical data, most patients can be controlled with doses of 80 ∼ 160 mg per day. Doses greater than 80 mg per day should be divided into two doses. 6) Maintenance therapy following intravenous induction to prevent rebleeding due to gastric or duodenal ulcers After intravenous induction to prevent rebleeding due to gastric or duodenal ulcers, administer 40 mg once daily for 4 weeks. 4. Renal impairment No dose adjustment is necessary. Use with caution because there is limited experience with administration to patients with severe renal impairment. 5. Hepatic impairment No dose adjustment is necessary in patients with mild to moderate hepatic impairment. Patients with severe hepatic impairment should not exceed a dose of 20 mg of this medicine. 6. Elderly patients No dose adjustment is necessary.

Children's dosage

Adolescents 12 years of age and older - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. Patients whose esophagitis has not healed or whose symptoms persist should take it for an additional 4 weeks. Adolescents 12 years of age and older - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: 20 mg once daily. If symptoms are not controlled after 4 weeks, further medical evaluation is needed. Once symptoms have resolved, subsequent symptoms may be controlled with 20 mg once daily. In adults, 20 mg may be taken once daily as needed. As-needed use to control recurring symptoms is not recommended for patients at high risk of gastric and duodenal ulcers due to nonsteroidal anti-inflammatory drug use. Children under 12 years of age - There is no experience with administering this medicine to children under 12 years of age.

Precautions

This medication should not be administered to certain patients. For instance, individuals who have allergies or have experienced hypersensitivity reactions to this medication or its ingredients, or to benzimidazole derivatives, should not take it. Additionally, those allergic to penicillin antibiotics or macrolide antibiotics should avoid concurrent use. It is also safe not to use this medication for patients currently taking certain cardiovascular medications, those with a history of myocardial infarction, and lactating women. While taking this medication, caution is necessary as various adverse reactions may occur. Gastrointestinal symptoms such as headaches, abdominal pain, diarrhea, nausea, and vomiting can commonly occur, and rarely hematological abnormalities, skin rashes, and liver function abnormalities may appear. Electrolyte imbalances such as muscle pain or hypomagnesemia can occur infrequently; consult a healthcare professional immediately if symptoms arise. If this medication is taken for a long period, regular testing is necessary, particularly monitoring magnesium levels and fracture risk when used for more than a year. This medication can reduce stomach acid, which may increase bacterial proliferation in the gastrointestinal tract, slightly raising the risk of infection; notify healthcare professionals immediately if diarrhea persists. This medication may have interactions with other drugs, so it is essential to inform your doctor or pharmacist if you are currently taking any medications. Caution is particularly needed when used alongside anticoagulants, antibiotics, antiviral medications, and anticonvulsants due to the risk of adverse effects from changes in blood concentration. Safety data for this medication during pregnancy is limited; hence, consult a doctor if you are pregnant or planning to become pregnant before using this medication. It is recommended that nursing mothers do not take this medication. In case of overdose, there is no specific antidote; therefore, appropriate treatment should be provided based on symptoms, and it should be kept out of reach of children in a safe place. This medication must be stored in its original container, and transferring it to another container should be avoided to maintain quality and safety.

Side effects

Leukopenia, thrombocytopenia, agranulocytosis, pancytopenia, fever, angioedema, anaphylactic reactions, shock, peripheral edema, hyponatremia, hypomagnesemia, insomnia, anxiety, mental confusion, depression, aggression, hallucinations, headache, dizziness, paresthesia, drowsiness, taste disorders, blurred vision, bronchospasm, pancreatitis, abdominal pain, constipation, diarrhea, abdominal bloating, nausea, vomiting, dry mouth, stomatitis, gastrointestinal candidiasis, microscopic colitis, increased liver enzymes, hepatitis, liver failure, encephalopathy, dermatitis, itching, rash, urticaria, hair loss, photosensitivity, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, Leal syndrome, acute generalized exanthematous pustulosis, drug reactions associated with eosinophilia and systemic symptoms, fractures, arthralgia, myalgia, muscle weakness, interstitial nephritis, gynecomastia, asthenia, hyperhidrosis, Clostridium difficile diarrhea, abdominal distension, allergic reactions, back pain, chest pain, sternal pain, facial edema, facial flushing, fatigue, influenza-like illness, general edema, leg edema, lethargy, pain, stiffness, tachycardia, flushing, hypertension, goiter, irritable bowel syndrome, exacerbation of constipation, dyspepsia, dysphagia, gastrointestinal malformation, epigastric pain, belching, esophageal disorders, frequent bowel movements, gastroenteritis, gastrointestinal bleeding, hiccups, black stools, oral disorders, pharyngeal disorders, rectal disorders, gastrointestinal symptoms, increased serum gastrin, tongue disorders, tongue edema, ulcerative stomatitis, earache, tinnitus, anemia, hypochromic anemia, cervical lymphadenopathy, nosebleeds, leukocytosis, leukopenia, thrombocytopenia, bilirubinemia, liver function abnormalities, elevated ALT, elevated AST, diabetes, hyperuricemia, elevated ALP, dry mouth, vitamin B12 deficiency, weight gain, weight loss, exacerbation of arthritis, arthropathy, seizures, fibromyalgia syndrome, hernia, polymyalgia rheumatica, loss of appetite, apathy, increased appetite, confusion, worsening depression, hypertonia, sensory loss, erectile dysfunction, insomnia, migraine, exacerbation of migraine, sleep disorders, tremors, visual field defects, dysmenorrhea, menstrual disorders, vaginitis, exacerbation of asthma, cough, dyspnea, laryngeal edema, pharyngitis, rhinitis, sinusitis, acne, anal itching, erythematous rash, papulovesicular rash, otitis media, altered smell, taste loss, taste distortion, urinary abnormalities, albuminuria, cystitis, dysuria, fungal infection, hematuria, urinary frequency, candidiasis, genital candidiasis, polyuria, conjunctivitis, visual disturbances, duodenitis, esophagitis, esophageal strictures, esophageal ulcers, esophageal varices, gastric ulcers, gastritis, benign polyps or nodules, Barrett's esophagus, mucosal discoloration, hernia, systemic lupus erythematosus, cutaneous lupus erythematosus, hypocalcemia, hypokalemia, rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and moisture, ideally at a temperature between 1 and 30 degrees Celsius. Proper storage helps maintain the medication's effectiveness for an extended period.

Appearance and packaging

Appearance

Pink round film-coated tablet

Package unit

28 tablets/box [14 tablets/PTP (Alu-Alu)*2]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.